Chonluten
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
5 – 10 mg
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Limited human trials
Chonluten
5-10 mg · Once daily
Molecular formula
C11H17N3O8
- Mol. weight
- 319.27 g/mol
- CAS number
- 75007-24-8
- PubChem
- 194641
- Developed · 1990s-2000s (developed as part of Khavinson's systematic organ-specific peptide bioregulator research program)
- Thorne Research / BioResource International
Thorne Research Inc.
Amino acid sequence
DGEA-GFOGER-GPQGIAG-GSKGPDRespiratory Tissue Repair
This peptide turns on genes that help your lung lining heal and rebuild, restoring the protective barrier in your airways.
Lung Inflammation Control
Calms down overactive immune signals in your lungs, reducing harmful inflammation that damages breathing tissue over time.
Age-Related Lung Protection
Long-term Russian studies suggest it may help preserve lung function in older adults, though evidence remains limited outside that research.
Dosing
How much do I take?
5 – 10 mg · once daily · subcutaneous
5 – 10 mg
Once daily
Covers all 2 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for respiratory health restoration in aging individuals with declining lung function & chronic bronchopulmonary conditions requiring tissue-level regenerative support
Best for
Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Chonluten with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Sublingual (enteric-coated capsules) · Subcutaneous injection
Route
Chonluten is administered Sublingual (enteric-coated capsules)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data.
As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed.
Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist.
Long-term safety outcomes are completely unstudied.
Evidence is limited to observational clinical use in Russian medical practice spanning several decades and small open-label studies, primarily published in Russian-language journals.
No preclinical safety studies, toxicology screening, pharmacokinetics, or randomized controlled trials with formal safety monitoring have been conducted. The literature base consists primarily of descriptive case reports and clinical experience rather than rigorous safety data.
Common side effects · experienced by some users
Injection site reaction
Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. Standard for injectable peptide bioregulators.
Management: Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Mild fatigue
Slight fatigue during initial days as bronchopulmonary immune function recalibrates and respiratory gene expression programs activate.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Transient respiratory changes
Mild increase in mucus production or slight changes in respiratory secretions as bronchial epithelial normalization occurs.
Management: Generally benign — indicates active epithelial remodeling. Stay hydrated. Should stabilize within several days.
Mild headache
Transient headache during the first few days of treatment, potentially related to immune activation and cytokine level adjustment.
Management: Ensure adequate hydration. Standard analgesics if needed. Usually self-limiting.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Chonluten
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Chonluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Vladonix (thymic peptide bioregulator — provides systemic immune support complementing Chonluten's bronchopulmonary specificity) — May be used together under medical guidance.
- Safe:Vilon (KE dipeptide — synergistic immunomodulation targeting T-cell function alongside Chonluten's respiratory focus) — May be used together under medical guidance.
- Safe:Epithalon (AEDG tetrapeptide — complementary pineal/melatonin bioregulator supporting circadian immune rhythms) — May be used together under medical guidance.
With medications
- Caution:Immunosuppressive medications (cyclosporine, tacrolimus) — Chonluten's immunomodulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
- Caution:High-dose systemic corticosteroids — may interfere with Chonluten's bronchial epithelial differentiation mechanisms — Use with caution—discuss with your healthcare provider.
- Caution:Other potent immunostimulants at high doses without medical supervision — risk of immune overactivation in pulmonary tissue — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Chonluten. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-10 (during treatment course)
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Chonluten is a peptide extract designed to support cartilage and joint health by providing building blocks and signaling molecules that promote cartilage cell survival and matrix repair.
The deeper mechanism
Chonluten is a bioactive peptide complex derived from cartilage tissue that contains multiple amino acid sequences and growth factor mimetics capable of activating chondrocyte anabolic pathways.
These peptides interact with integrin receptors and growth factor receptors on cartilage cells, upregulating expression of type II collagen, aggrecan, and other extracellular matrix components while simultaneously suppressing catabolic enzymes like matrix metalloproteinases (MMPs) through MAPK and Wnt/β-catenin pathway modulation.
What to expect
Days 1-10 (during treatment course)
What you might notice
- Minimal noticeable changes initially — epigenetic mechanisms targeting bronchopulmonary genes are building
- Possible mild injection site reactions or respiratory changes as epithelial remodeling begins
- Mild fatigue as pulmonary immune function adjusts
- DNA minor groove binding at ATTTC sequences is activating respiratory gene transcription
What's normal
- Effects are subtle at first — Chonluten works at the gene expression level through DNA promoter binding
- Ki-67 and p53 normalization in bronchial epithelium is beginning but cellular turnover takes days to weeks
- TNF tolerance induction in alveolar macrophages is starting to reduce inflammatory signaling
What's next
- Continue daily administration for the full course duration (10-20 days)
- Respiratory improvements will continue building as epithelial differentiation progresses
- The most significant cellular changes occur during and shortly after the treatment course
Week 2-6 (during and after treatment)
What you might notice
- Improved respiratory comfort and breathing capacity
- Enhanced mucociliary clearance and reduced respiratory congestion
- Better resilience against respiratory infections and environmental irritants
- Improved energy levels as pulmonary gas exchange normalizes
What's normal
- Bronchial epithelial differentiation is significantly improved with normalized cell turnover
- Alveolar macrophage inflammation is substantially reduced through TNF tolerance
- Pro-inflammatory cytokine levels (IL-1β, IL-6, TNF-α) are markedly decreased
- These molecular changes translate into functional respiratory improvements over weeks
What's next
- Benefits continue developing for weeks after the treatment course ends
- Epigenetic modifications to bronchopulmonary gene expression persist beyond active treatment
- Plan the next course in 3-6 months to reinforce and extend benefits
Month 2-6 (inter-course period)
What you might notice
- Sustained improvements in respiratory function and pulmonary defense
- Ongoing geroprotective benefits from persistent bronchial epithelial normalization
- Reduced frequency and severity of respiratory issues
- Benefits may gradually diminish over months, indicating readiness for the next course
What's normal
- Epigenetic modifications to bronchopulmonary genes persist beyond active treatment
- Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
- Each subsequent course reinforces and extends benefits from previous treatments
- Long-term clinical follow-up supports sustained benefits with repeated courses over years
What's next
- Begin the next Chonluten course after 3-6 months
- Consider combining with complementary bioregulators (Vladonix, Epithalon) in rotation
- Comprehensive anti-aging protocols may use Chonluten alongside other organ-specific peptides
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Chonluten over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is Chonluten and what organ does it target?
Chonluten is a synthetic tripeptide (Glu-Asp-Gly or EDG) classified as T-34 in Khavinson's bioregulator system, specifically designed to target the bronchopulmonary system — the lungs and bronchial tree. It was developed by Professor Vladimir Khavinson as part of his systematic research program identifying organ-specific ultrashort peptides. Chonluten restores respiratory epithelial function through direct DNA interaction at bronchopulmonary gene promoters, normalizing bronchial mucosa differentiation and reducing pulmonary inflammation.
How does Chonluten differ from general immune peptides like Vilon or Thymalin?
While Vilon (KE dipeptide) and Thymalin provide systemic immune modulation through thymic T-cell activation, Chonluten specifically targets bronchopulmonary tissue. Its EDG sequence binds to ATTTC DNA sequences found in lung-specific gene promoters, activating respiratory epithelial differentiation programs rather than general immune pathways. Think of it as the lung-specialist bioregulator in the Khavinson system, while Vilon is the immune-specialist and Epithalon the pineal-specialist.
Can Chonluten help with chronic respiratory conditions?
Chonluten has been studied for its ability to restore bronchial epithelial function through normalization of Ki-67 and p53 expression — markers of cell proliferation and apoptosis that become disrupted in chronic respiratory disease. By restoring proper epithelial cell turnover, goblet cell function, and mucociliary clearance, it addresses tissue-level dysfunction underlying chronic respiratory conditions. However, it should not replace established respiratory medications and should be used under medical supervision alongside standard treatments.
Is Chonluten available as an oral supplement?
Yes, Chonluten is available in enteric-coated capsule form designed for oral administration, in addition to injectable formulations. The oral capsules are manufactured by the Peptide Bioregulator Company and are widely available as dietary supplements in Russia and several CIS countries. The enteric coating protects the EDG tripeptide from gastric degradation, allowing absorption through intestinal peptide transporters.
How does the TNF tolerance mechanism protect the lungs?
TNF tolerance is a protective adaptation where alveolar macrophages become resistant to excessive TNF-α stimulation while maintaining their ability to respond to pathogens. Chonluten induces this state by modulating MAP kinase phosphorylation and reducing cell-endothelial adhesion in pulmonary tissue. This prevents the damaging cycle of uncontrolled inflammation that occurs in cytokine storms, chronic obstructive conditions, and age-related pulmonary inflammation — essentially training the lung's immune cells to respond proportionally rather than excessively.
What is the recommended treatment schedule for long-term respiratory health?
The standard Khavinson protocol recommends treatment courses of 10-20 days repeated every 3-6 months. For comprehensive geroprotective therapy, Chonluten is often rotated with complementary bioregulators: Vladonix (thymic/immune), Epithalon (pineal/melatonin), and other organ-specific peptides. Long-term clinical follow-up over 6-8 years has demonstrated sustained benefits with this cyclical approach, including reduced mortality in elderly populations when Chonluten is part of a comprehensive bioregulator program.
Further reading
History & related research
History · since 1994
Restoring the Breath: A Peptide Revolution in Respiratory Medicine
Chonluten is a synthetic tripeptide bioregulator derived from lung tissue, specifically targeting the restoration and normalization of respiratory system function. Developed by Vladimir Khavinson at the St.
Read the full history of ChonlutenReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Chonluten, on one page.